Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2013-06-21
2015-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis, a study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
The investigators major research hypothesis is:
* By comparing patients with vs without postural instability, but also in comparison to controls, the investigators main research neurophysiological hypothesis is that patients with postural instability will display an impaired braking.
* This impaired braking could be partly explained by a dysfunction and/or lesion of the basal ganglia and brain stem structures, corresponding to the investigators main neuroradiological hypothesis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
NCT00956501
Does Improved Ability to Achieve Single Leg Stance Lead to a More Efficient Gait Pattern in Adults With Acquired Brain Injury?
NCT04062149
Gait Disorders in Patients With Cognitive Decline
NCT03399591
Assessment of Accelerometric Measurement Devices for Gait Analysis
NCT01522690
Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease
NCT01502995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In PD patients, which represent a model of basal ganglia system dysfunction, length and velocity of the first step during gait initiation are known to be reduced and improved by dopaminergic therapy whereas postural instability is less sensitive to the treatment suggesting the involvement of other brain structures dysfunction and/or lesion. One way to evaluate the postural control during the gait initiation process is to measure the vertical velocity of the centre of gravity by using a force platform. In healthy adults, during the single support phase, a forward fall of the centre of gravity occurs and is actively reversed by the stance leg soleus muscle activation prior foot contact. In parkinsonian patients with postural instability, this phenomenon, called active braking, is altered. It is assumed that this postural instability results from additional lesions and/or dysfunction in the basal ganglia output structures, especially in the midbrain, containing the pedunculopontine nucleus and the mesencephalic locomotor region, two structures known to participate to the control of locomotion and posture in animals.
This research program will focus on gait initiation and postural control in ALS patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis. A study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
If the investigators get a deeper understanding of the neural substrates underlying the hypothetical impairment of gait initiation and postural control, the investigators will then be able to develop adequate therapeutical strategies (pharmacological interventions, surgical therapies, rehabilitation programs) aimed at improving movement preparation and gait execution in ALS patients
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
Healthy
No interventions assigned to this group
ALS with postural instability
ALS with postural instability
No interventions assigned to this group
ALS without postural instability
ALS without postural instability
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a defined, probable or laboratory possible ALS according to El Escorial18
* With a disease duration between 3 months (inclusive) and 5 years (exclusive)
* Able to walk at least 10 meters without an aid and to perform the foot-tapping task
* Right handed
* Able to understand thoroughly the given information; able to sign the informed consent form (signature of spouse or family relative or acceptable third party is acceptable if the patient is physically unable to sign)
* With a social insurance
Exclusion Criteria
* Patients with any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment
* Patients with any major evolving psychiatric disorder or major anxiety disorder according to DSM-IV criteria (APA, 1996)
* Patients with contraindications for the MRI scan
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement
UNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre François Pradat, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital 75013 Paris France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Abidi M, de Marco G, Grami F, Termoz N, Couillandre A, Querin G, Bede P, Pradat PF. Neural Correlates of Motor Imagery of Gait in Amyotrophic Lateral Sclerosis. J Magn Reson Imaging. 2021 Jan;53(1):223-233. doi: 10.1002/jmri.27335. Epub 2020 Sep 7.
Abidi M, de Marco G, Couillandre A, Feron M, Mseddi E, Termoz N, Querin G, Pradat PF, Bede P. Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes. Eur J Neurol. 2020 Jan;27(1):121-128. doi: 10.1111/ene.14042. Epub 2019 Aug 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-A01247-36
Identifier Type: REGISTRY
Identifier Source: secondary_id
GAITALS-C12-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.